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The mechanisms that regulate the 
incorporation and release of tissue factor (TF) 
into cell-derived microparticles are as yet 
unidentified. In this study we have explored 
the regulation of TF release into 
microparticles by the phosphorylation of the 
serine residues within the cytoplasmic domain 
of TF. Wild-type and mutant forms of TF, 
containing alanine and aspartate substitutions 
at Ser253 and Ser258 were overexpressed in 
coronary artery and dermal microvascular 
endothelial cells and microparticle release 
stimulated with PAR2-agonist peptide 
(PAR2-AP). The release of TF antigen and 
activity was then monitored. In addition, the 
phosphorylation state of the two serine 
residues within the released microparticles 
and also the cells was monitored over 150 
min. The release of wild-type TF as 
procoagulant microparticles peaked at 90 min 
and declined thereafter in both cell types. The 
TF within these microparticles was 
phosphorylated at Ser253 but not at Ser258. 
Aspartate-substitution of Ser253 resulted in 
rapid release of TF antigen but not activity, 
whereas TF release was reduced and delayed 
by alanine-substitution of Ser253 or 
aspartate-substitution of Ser258. Alanine-
substitution of Ser258 prolonged the release 
of TF following PAR2-AP activation. The 
release of TF was concurrent with 
phosphorylation of Ser253 and was followed 
by dephosphorylation at 120 min, and 
phosphorylation of Ser258. We propose a 
sequential mechanism in which the 
phosphorylation of Ser253 through PAR2 
activation results in the incorporation of TF 
into microparticles, simultaneously inducing 
Ser258 phosphorylation. Phosphorylation of 
Ser258 in turn promotes the 
dephosphorylation of Ser253 and suppresses 
the release of TF. 
 
Increased levels of circulating endothelial-
derived microparticles are recognised as a cause 
and prognostic marker for vascular disease and 
injury (1-3). Moreover, these microparticles 
have been shown to be able to support the 
induction of thrombosis through a TF-dependent 
mechanism (3,4). The mechanisms that regulate 
the incorporation and release of TF into cell-
derived microparticles are as yet unidentified. 
Furthermore, it appears that cellular activation 
(5) for example through activation of protein 
kinase-C (PKC) (6) can induce microparticle 
release although this is not completely 
understood. The proteolytic activation of PAR2 
by enzymes such as factor Xa and trypsin is 
known to result in the translocation of PKCα to 
the membrane (7). The release of TF into 
membrane-derived vesicles on incubation of 
cells with trypsin has been demonstrated (8). 
Furthermore, PKCα is known to phosphorylate 
the cytoplasmic domain of TF at Ser253 (7,9), 
while Ser258 is part of a proline-directed kinase 
(PDK) consensus sequence (10) which becomes 
phosphorylated separately (11), initiated through 
the phosphorylation of Ser253 (9). 
The cytoplasmic domain of TF is not 
required for the procoagulant activity of TF or 
de-encryption of this protein (12,13). Moreover, 
it has been reported that substitution of the 
cytoplasmic domain of TF with the cytoplasmic 
domain of decay-accelerating factor does not 
alter the release of TF in cells that are capable of 
releasing TF-containing microparticles without 
activation (14). However, it is known that cells 
spontaneously release decay-accelerating factor 
under standard culture conditions (15). In this 
study, by aspartate-substitution (to mimic 
phosphoserine) (16) or alanine-substitution (to 
prevent phosphorylation) of two of the serine 
residues within the cytoplasmic domain of TF, 
we investigated the contribution of these 
residues to the regulation of TF incorporation 
and release into cell-derived microparticles. 
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EXPERIMENTAL PROCEDURES 
Plasmid vectors- The pCMV-XL5-TF plasmid 
for the expression of full-length human TF was 
obtained from OriGene. Aspartate and alanine 
substitutions at Ser253 and Ser258 were carried 
out to produce mutated constructs (pCMV-XL5-
TFAsp253, pCMV-XL5-TFAla253, pCMV-XL5-
TFAsp258 and pCMV-XL5-TFAla258) or 
alternatively combinations of these mutants (see 
supplemental material). 
Cell culture, transfection and microparticle 
isolation- Human coronary artery endothelial 
cells (HCAEC), dermal microvascular 
endothelial cells (HDMEC) and umbilical vein 
endothelial cells (HUVEC) (PromoCell) were 
used throughout the investigation since unlike 
monocytes or tumour cells, these cells do not 
either constitutively express TF and/or 
spontaneously release microparticles. HCAEC 
have been shown to express PAR2 on the cell 
surface (17) whereas HUVEC are devoid of this 
receptor and can therefore be used without 
signalling contribution from this receptor. Cells 
were transiently transfected with the wild-type 
or mutant forms of pCMV-XL5-TF plasmid (1 
µg) and allowed to express TF for 48h 
(supplemental material). The expression of TF 
was confirmed by measuring TF mRNA and 
total and cell-surface antigen levels 
(Supplemental Figure I). In some experiments, 
the cells were then transfected with peptides 
corresponding to the last 18-amino acids within 
the cytoplasmic domain of TF 
(RKAGVGQSKENWSPLNVS) synthesised in 
unphosphorylated form (Ser253/Ser258), 
phosphorylated on the first serine 
(pSer253/Ser258), the second serine 
(Ser253/pSer258), double-phosphorylated 
(pSer253/pSer258) and a random-peptide. The 
peptides were prepared and confirmed using the 
Merrifield procedure as before (18), and 
transfected using the Chariot reagent (Active 
Motif) as previously described (19). All cells, 
including untransfected samples, were then 
transferred to serum-free medium (SFM) (1 ml) 
for 1.5h, stimulated with either PAR1 agonist 
peptide (TFLLR; 20 µM), PAR2 agonist peptide 
(PAR2-AP; SLIGRL; (20 µM) (Sigma Chemical 
Company), a synthetic scrambled-PAR2 agonist 
peptide (IRLSGL) (20 µM), a random peptide or 
recombinant human factor Xa (10 nM) 
(American Diagnostica). For comparison, 
HUVEC transiently transfected to overexpress 
TF were activated with TNFα (10 ng/ml) or IL-
1β (10 ng/ml). Released cell-derived 
microparticles were isolated from media 
according to published procedures (17,20). In 
some experiments, Calyculin-A (1 nM) was 
added to the cells 30 min prior to activation, to 
inhibit cellular phosphatase 1/2A activities. The 
pellet was resuspended in 1 ml of PBS, divided 
into batches and frozen at -80°C or used 
immediately. For comparison, in some 
experiments, microparticles from THP-1 cells, 
isolated peripheral blood monocuclear cells 
(PBMC) or human coronary artery smooth 
muscle cells (HCASMC) prepared as before 
(17), were analysed alongside. Furthermore, in 
order to compare and contrast the TF content 
and phosphorylation state of TF within the 
endothelial cell-derived microparticles, to those 
found naturally within the circulation in healthy 
and diseased conditions, microparticles were 
also isolated from the plasma of cancer and 
cardiovascular patients, or normal subjects 
(Innovative Research). 
Analysis of microparticle density, phospholipid 
content and TF antigen and activity- The 
concentration of microparticles in each sample 
was determined using the Zymuphen 
Microparticle Assay Kit (Hyphen BioMed) and 
by flow cytometry using FITC-conjugated-anti-
TF antibody (American Diagnostica). Total TF 
antigen within each isolated sample was 
measured using a TF-ELISA kit (Affinity 
Biologicals) as described before (19). Activities 
of TF-containing and control microparticles 
were measured using a chromogenic assay based 
on quantifying the activity of the generated 
thrombin, as previously described (20). 
Additionally, aliquots (1 ml) of the wild-type, 
the mutant forms of TF-containing- and control 
microparticles were freeze-dried and the 
phosphatidylserine (PS):phosphatidylcholine 
(PC) ratios determined by thin layer 
chromatography as described in the 
supplemental material. 
Western blot analysis of Ser253 and Ser258 
phosphorylation within TF- HCAEC or 
microparticles were lysed in phosphosafe-lysis 
buffer (Active Motif) and the concentrations of 
total protein and TF antigen determined using 
Bradford protein-estimation assay and ELISA 
respectively. Microparticle lysates were 
immunoprecipitated using anti-TF antibody-
conjugated agarose beads as before (21) prior to 
western blot analysis. To assess the ratios of 
phosphorylated:total TF in the cell lysates, 
equivalent amounts of TF protein were 
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examined for phosphoserine (PKC-substrate 
consensus), phospho-Ser258-TF, and for total 
TF by western blot as described in the 
supplemental material. 
Measurement of cell apoptosis- Sets of HCAEC 
(5×104), transfected to overexpress the wild-type 
or mutant forms of TF, were stimulated with 
PAR2-AP as before and cellular apoptosis was 
measured at 90 and 150 min and 6h using the 
DeadEnd fluorescence-based TUNEL assay 
(Promega). Caspase-3/7 activation was measured 
by flow cytometry as previously described (22). 
Statistical analysis- All data represent the 
calculated mean values from the number of 
experiments stated in each figure legend ± the 
calculated standard error of the mean. Statistical 
analysis was carried out using the Statistical 
Package for the Social Sciences (SPSS Inc.). 
One-Way ANOVA procedure was used for the 
analysis of variance of data against the control 
with Tukey's honestly significant difference test 
to highlight statistically significant differences. 
RESULTS 
Plasmid transfection efficiency of the cells 
was consistently above 35% and 32% in 
HCAEC and HDMEC respectively. Following 
transient transfection of the cells, the expression 
of TF protein increased within 24h and remained 
constant for up to 3 days. Furthermore, levels of 
cellular TF mRNA and total and cell-surface TF 
protein expression were consistent between 
wild-type TF and mutant forms of TF 
(Supplemental Figure I). Transfection 
efficiencies of greater than 75% were obtained 
for the peptides, tested using a fluorescent-
labelled TF-peptide which also appeared to be 
evenly distributed throughout the cell. 
Time-course of TF release as microparticles, 
upon PAR2 activation. Stimulation of HCAEC 
or HDMEC overexpressing TFWt with either 
PAR2-AP (20 µM) or FXa (10 nM) resulted in 
the transient incorporation and release of TF 
antigen into microparticles, which peaked at 90 
min post-stimulation (Figure 1A) but not in the 
untransfected (but PAR2-AP activated) cells, 
PAR1-activated cells or PAR2-AP-activated 
HUVEC (not shown). Moreover, incubation of 
cells with the scrambled-PAR2-AP or random 
peptide did not result in the release of 
microparticles. Furthermore, incubation of TF-
overexpressing HUVEC with either TNFα (10 
ng/ml) or IL-1β (10 ng/ml) did not induce TF 
release at 90 min, but significant amounts of TF 
were released by HUVEC at 6h post-activation 
(Supplemental Table IA). The release of 
microparticles by HCAEC was also measured by 
flow cytometry and reflected the increased 
proportion of TF-containing microparticles 
compared to control microparticles at 90 min 
(Supplemental Figure II). However, since 
microparticles are readily taken up by 
endothelial cells in culture [17] (and 
Supplemental Figure III), it has to be noted that 
the observed changes in TF concentrations in the 
media represent the net flux of the TF-containing 
microparticles. Increases in released TF antigen 
concentrations were concurrent with increased 
TF activity as measured using the chromogenic 
assay (Figure 1B). In contrast, neither the total 
protein concentration nor the released 
microparticle densities were significantly altered 
between the samples (Supplemental Table II). 
The values for endothelial cell-derived 
microparticle densities, TFwt concentrations and 
TFwt:microparticle ratios were in line with those 
isolated from similar volumes of patient plasma 
or media from activated THP-1, PBMC and 
HCASMC. Moreover, the PS to PS+PC 
percentage in the TF–containing microparticles 
remained constant between the various samples. 
Finally, we have previously demonstrated the 
lack of Tsg101 and therefore, the absence of 
exosomes from our preparations of HCAEC-
derived microparticles (17). 
The influence of Ser253 and Ser258 
mutations on the release of TF. Substitution of 
Ser253 with aspartate (TFAsp253), to mimic 
phosphoserine resulted in the accelerated release 
of TF antigen peaking at 45 min (Figure 1C) but 
was not reflected in the released TF activity 
which peaked at 90 min (Figure 1D). This may 
due to the lower proportions of incorporated PS 
as seen at 45 min (Supplemental Table II), which 
is pre-requisite for the procoagulant activity of 
TF and is in agreement with previous reports 
(23). In contrast, alanine-substitution of Ser253 
(TFAla253) suppressed the release of TF antigen 
and activity. Aspartate-substitution of Ser258 
(TFAsp258) resulted in both reduction, and delay 
of TF release. Furthermore, alanine-substitution 
of this residue (TFAla258) resulted in the release of 
TF which was dependent on PAR2 activation but 
did not subside after 90 min. Furthermore, 
replacement of microparticle-containing 
conditioned medium with fresh medium at 90, 
120 and 150 min, did not result in the depletion 
of TF release which reappeared within 30 min 
(Supplemental Figure III). Moreover, incubation 
of microparticles with cells resulted in uptake. 
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Finally, double-aspartate substitution 
(TFAsp253/Asp258) resulted in a pattern of TF release 
that was similar to that of TFAsp253 alone, while 
TFAla253/Ala258 or TFAla253/Asp258 mutants did not 
induce the release of TF (not shown). 
The influence of TF Ser253 and Ser258 
mutations on cell survival. No cell apoptosis was 
observed at 90 or 150 min following activation 
of HCAEC or HDMEC with PAR2-AP 
(Supplemental Table III). Activation of HCAEC 
or HDMEC transfected with either TFWt or 
TFAsp253 reduced the rate of cellular apoptosis 
compared to the control cells at 6h, small 
increases in cell apoptosis were observed on 
activation of cells overexpressing TFAla253 
(Supplemental Figure IV) which was preceded 
by enhanced caspase-3/7 activity in these cells at 
5h (not shown). Activation of untransfected cells 
with PAR2-AP did not induce cellular apoptosis. 
Incubation of HUVEC with TNFα or IL-1β 
resulted high levels of cell apoptosis in all 
treated samples at 6h but not at 90 min 
(Supplemental Table IB and Supplemental 
Figure V). 
Analysis of the phosphorylation state of 
Ser253 and Ser258 within microparticle-
associated TF, The phosphorylation state of 
Ser253 within TFWt-microparticles was 
evaluated following immunoprecipitation of TF 
from HCAEC and HDMEC-derived 
microparticles isolated at 90 min. TF protein was 
present in the microparticles isolated from the 
media of TF-transfected HCAEC and HDMEC, 
the plasma of patients, activated THP-1 and 
PBMC, HCASMC and from TNFα and IL-1β-
treated HUVEC at 6h, was lower in the 
microparticles from the healthy plasma and there 
was no detectable TF in the media of 
untransfected HCAEC or HDMEC 
(Supplemental Table II). TFWt was recognised by 
an anti-phospho-PKC-substrate antibody in all 
TF-containing microparticles. However, except 
in TNFα and IL-1β-treated HUVEC, none of the 
cell-derived microparticles were recognised by 
the anti-phospho-Ser258 TF antibody (Figure 2) 
suggesting that the released TFWt in 
microparticles is phosphorylated at Ser253 
alone. No microparticles could be isolated from 
cells following activation with the scrambled-
PAR2-AP. 
Time-course of the phosphorylation of 
Ser253 and Ser258 within TF on activation with 
PAR2-AP. Incubation of TFwt-overexpressing 
HCAEC with PAR2-AP resulted in peak 
phosphorylation ratio of Ser253 (to total TF), at 
90 min (Figure 3A) which correlates with the 
observed release of TF at 90 min. The level of 
phosphorylation declined at >120 min which 
suggests dephosphorylation of this residue. In 
contrast, little phosphorylation of Ser253 was 
observed in the cells expressing TFAsp258 and no 
phosphorylation was detected on incubation of 
HCAEC overexpressing TFWt with the 
scrambled-PAR2-AP. Analysis of Ser258 
phosphorylation following stimulation with 
PAR2-AP showed increased phosphorylation of 
Ser258 at 120 min in TFWt and TFAsp253 (Figure 
3B) but no phosphorylation in the cells 
expressing TFAla253 (not shown). Moreover, a 
second earlier Ser258 phosphorylation peak was 
detected at 45 min in cells expressing TFAsp253. 
No apoptosis was observed in any of the cell 
samples for the duration of the assays 
(Supplemental Table III). 
Release of TF in the presence of peptides 
corresponding to TF cytoplasmic domain. 
Transfection of TFWt-overexpressing HCAEC 
cells with either pSer253/Ser258 or 
pSer253/pSer258 peptide, followed by 
stimulation with PAR2-AP resulted in increased 
and accelerated (60 min) release of TF (Figure 
4A). Furthermore, the release of TF was reduced 
on transfection with the Ser253/pSer258 peptide. 
Time course analysis of the TF content of 
microparticles, isolated from cells transfected 
with pSer253/Ser258 peptide showed an 
accelerated rate of wild-type TF release in these 
cells (Figure 4B). In contrast, the 
phosphorylation state of Ser253 in these cells 
was not significantly increased at 45 min 
although there was a significant level of Ser253 
phosphorylation in both peptide-transfected 
(Figure 4B) and untransfected cells (Figure 3A). 
In addition to measuring the release of TF, the 
phosphorylation state of Ser258 in the above 
cells was analysed. Transfection of cells with 
either pSer253/Ser258 or pSer253/pSer258 
induced the phosphorylation of Ser258 which 
peaked at 90 min (Figure 4C) upon activation 
with PAR2-AP only. No cellular apoptosis was 
observed in any of the cell samples during the 
assays (Supplemental Table IV). 
Finally, in the absence of Calyculin-A, 
transfection of cells with Ser253/pSer258 
resulted in decreases in TFAla258 release at 90 min 
(Figure 4D) and was concurrent with the 
reduction in Ser253 phosphorylation in these 
cells (Figure 4E). However, the inclusion of 
Calyculin-A partially restored TFAla258 release 
(Figure 4D) and was reflected in the maintained 
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phosphorylated state of Ser253 (Figure 4E). In 
agreement, the release of TFAsp258 at 90 min 
(Figure 4F) and the phosphorylation of Ser253 
(Figure 4G) were partially restored in the 
presence of Calyculin-A. 
DISCUSSION 
The function of endothelial-derived 
microparticles as carriers of TF and their 
procoagulant properties, during disease has 
recently become established and discussed 
before (1-5,23-27) and is beyond the scope of 
this study. We have explored the regulation of 
the incorporation and release of TF into 
microparticles and our data suggest that PKC-
mediated phosphorylation of Ser253 within TF 
(7) acts as an “on-switch” to initiate the 
incorporation of TF into microparticles (Figure 
5). However, this is unlikely to be a coordinator 
for the formation and release of microparticles 
themselves. Therefore, these processes must be 
induced through other mechanisms that arise 
from PAR2 activation. In fact, activation of 
PAR1 by thrombin has been shown to induce the 
release of microparticles from endothelial cells 
through activation of Rho-kinase-II and caspase-
2 (24). Furthermore, TNFα has been shown to 
induce microparticle formation through the p38 
MAPK pathway (25). Our data suggest that the 
rapid short-term release of TF on engagement of 
PAR2 with its agonist peptide occurs as a 
consequence of the activation of the endothelial 
cells, and is distinct from the prolonged TF-
microparticle release observed due to cell 
apoptosis (26) induced by TNFα and IL-1β 
reported at 24h (27). Moreover, the presence of 
phosphorylation at Ser253 but not Ser258 in 
endothelial-derived TF-microparticles, isolated 
PBMC and THP-1 leukocytes, and smooth 
muscle cells was in agreement with the complex 
sets of microparticles isolated from patients’ 
plasma, which contain microparticles from these 
sources as well as platelets. This observation 
further supports the presence of a mechanism 
that regulates the release of TF following cell 
activation. 
Comparison of the TF protein sequence from 
a set of mammals shows that the serine residue 
at the position equivalent to Ser253 in humans is 
conserved in 6 out of the 9 species (Figure 6). It 
is possible that the release of TF in species 
without this phosphorylation site (murine, 
porcine and rat) is regulated by microparticle 
formation alone, and the hydrophilic residue at 
this position is sufficient for this purpose. It has 
been reported that substitution of the 
cytoplasmic domain of TF with that of decay-
accelerating factor does not alter TF release by 
smooth muscle cells (14). However, decay-
accelerating factor is spontaneously released by 
cells under normal culture conditions (15) and 
also smooth muscle cells spontaneously release 
microparticles. Therefore, we propose that the 
cytoplasmic domain of TF controls the 
incorporation of TF into microparticles in cells 
that actively regulate TF release, including 
endothelial cells. 
The phosphorylation of Ser253 within TF, 
together with other PAR2-initiated 
mechanism(s) initiates the activation of an as yet 
unidentified PDK (9) which phosphorylates 
Ser258 (Figure 3). In cells expressing TFAsp253, 
the second earlier Ser258 phosphorylation peak 
at 45 min suggests that the phosphorylation of 
Ser258 is dependent on, and possibly initiated by 
previous phosphorylation of Ser253. The 
phosphorylation of Ser258 appears to either 
enhance the activity of phosphatases 1/2A 
(Figure 4) or alternatively permit the 
dephosphorylation of Ser253 through structural 
alterations within the cytoplasmic domain of TF 
(28). In support of this hypothesis, the phospho-
Ser258-Pro259 motif is a potential recognition 
site for the peptidylprolyl cis/trans isomerase-1 
Pin1 (29) which may be capable of inducing 
conformational changes within proteins that 
contain the consensus motif (30). Little 
phosphorylation of Ser253 was observed in cells 
expressing TFAsp258 suggesting that Ser258 
phosphorylation can accelerate, or even induce 
the dephosphorylation of Ser253 and 
corroborates the function of Ser258 as an off-
switch for TF release. The presence of a 
conserved serine/threonine residue at this 
position, within a PDK-consensus sequence, in 
all the species indicated in figure 6, further 
emphasises a crucial function for this residue 
and the participation of a specific PDK enzyme, 
the identity of which we are pursuing. Moreover, 
although the rate of Ser253 dephosphorylation 
appears to have been enhanced by the presence 
of phospho-Ser258, the mechanism also appears 
to require PAR2 activation. 
Phosphorylation of Ser258 may become 
possible as a consequence of structural 
alterations in the cytoplasmic domain of TF 
induced by the phosphorylation of Ser253 (28). 
Similarly, dephosphorylation of phospho-Ser253 
may become permissible as a consequence of 
structural alterations brought about by Ser258 
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phosphorylation. Consequently, such changes in 
phosphorylation would only involve the TF 
molecule itself. Alternatively, changes in the 
phosphorylation state of TF may induce 
signalling mechanisms which then feedback on 
TF. Under these circumstances, every TF 
molecule can influence other TF molecules. To 
determine the underlying mechanisms, peptides 
corresponding to the last 18-amino acids in the 
C-terminal of TF including the two serines, were 
synthesised with different phosphorylation states 
and transfected into the cells prior to stimulation 
with PAR2-AP. The ability of phospho-Ser253 
peptides to accelerate the rate of TF release 
further supports the role of Ser253 as the on-
switch. Furthermore, the phosphorylated form of 
Ser253 appears to be capable of inducing TF 
release regardless of the phosphorylation state of 
Ser258. Intriguingly, while the rate of TF release 
was accelerated in these cells, the rate of Ser253 
phosphorylation was not significantly altered 
during these time-points (Figure 4B). This 
finding indicates that although Ser253 
phosphorylation may directly influence TF 
release, it also initiates independent events that 
alter the function of proteins which form the 
machinery required for the incorporation of TF 
into microparticles. Such events may include 
interactions with cytoskeletal proteins (16) or the 
activation of signalling mechanisms (Ettelaie et 
al unpublished data). In contrast, transfection of 
cells with either peptide in the absence of PAR2 
activation, or when using scrambled-PAR2-AP 
failed to initiate the release of TF into 
microparticles and supports the requirement for 
separate mechanisms for microparticle 
formation. Finally, no TF-microparticles could 
be isolated from PAR2-AP treated TF-
overexpressing embryonic HUVEC, devoid of 
PAR2 (Supplemental Table II). Interestingly, 
despite the accelerated rate of Ser258 
phosphorylation by these peptides in HCAEC 
(Figure 4C), no suppression of TF release was 
observed until 90 min (Figure 1A). Therefore, 
we suggest that as well as Ser258 
phosphorylation, dephosphorylation of Ser253 
also requires the induction of signalling 
mechanisms arising from PAR2 activation and 
may take up to 90 minutes to become effective. 
Such mechanisms may also involve alterations 
in the structure of the cytoplasmic domain of TF 
by proteins such as Pin1 (28) leading to 
dephosphorylation events (29) and acting as a 
time-dependent switch (30). Overexpression of 
TFAla258 in HCAEC did not lead to the 
suppression of TF release (Figure 1C). This 
continuous release of TF after 90 min, was 
shown to be due to a possible interruption in the 
“off-switch” rather than the stabilisation of the 
microparticles within the medium (Supplemental 
Figure III). However, subsequent transfection of 
these cells with the Ser253/pSer258 peptide did 
suppress TF release (Figure 4D), through a 
mechanism probably involving the induction of 
phosphatase activation (Figure 4E). Moreover, 
the ability of Asp258 to suppress TF release was 
partially reversed by the inhibition of 
phosphatase 1/2A activities (Figure 4F). 
However, the level of Ser253 phosphorylation 
(Figure 4G) was comparable to that observed 
with TFAla258 + Ser253/pSer258 peptide (Figure 
4E). Therefore, these data indicate that the 
suppression of TF release by Ser258 
phosphorylation involves the co-ordination of 
signalling mechanisms by TF itself, although we 
cannot dismiss possible additional contributions 
from conformational changes within the TF 
protein (28). 
In conclusion, we hypothesise that Ser253 
phosphorylation induces the incorporation and 
release of TF, while the phosphorylation of 
Ser258 acts to regulate the incorporation of TF 
into released microparticles through 
dephosphorylation of Ser253. Therefore, we 
have identified opposing regulatory roles for the 
two serine residues within the cytoplasmic 
domain of TF, in the incorporation of TF into 
microparticles, in cells that stringently regulate 
TF release. 
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FIGURE LEGENDS 
Fig. 1. Analysis of the release of wild-type and mutant forms of TF in microparticles. HCAEC and 
HDMEC (2×105) overexpressing TFWt or untransfected, were placed in SFM and activated with either 
PAR2-AP, scrambled-PAR2-AP (20 µM) or recombinant FXa (10 nM) and microparticles were 
isolated from the media. (A) TF antigen concentrations were determined by ELISA (n=7) and (B) TF 
activities of microparticles were measured using a chromogenic assay (n=7). HCAEC and HDMEC 
(2×105) overexpressing TFAsp253, TFAla253, TFAsp258 or TFAla258 in SFM, were activated with PAR2-AP 
and the microparticles isolated. (C) TF antigen concentrations (n=6) and (D) TF activities of 
microparticles (n=6) were determined. (*=p<0.05 vs. respective time zero sample). 
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Fig. 2. Analysis of the phosphorylation of Ser253 and Ser258 in microparticles. Microparticles 
were isolated at 90 min from HCAEC and HDMEC (2×105) overexpressing TFWt or control cells, 
plasma of three patients, one healthy individual and media of THP-1, isolated PBMC and HCASMC 
and HUVEC treated with TNFα or IL-1β. TF was immunoprecipitated and (A) phosphorylation of 
Ser253 measured using an anti-phospho-PKC-substrate antibody. (B) Phosphorylation of Ser258 was 
measured using the anti-phospho-Ser258 TF antibody. Cell-derived microparticles micrographs 
represent 5 preparations; patient plasma-microparticles represent duplicates. The quantity of TF in the 
isolated microparticles prior to immunoprecipitation is outlined in Supplemental Table II. 
Fig. 3. Analysis of the phosphorylation of Ser253 and Ser258 in cells. (A) HCAEC (2×105) 
overexpressing TFWt or TFAsp258, in SFM were activated with PAR2-AP (20 µM). The cells were lysed 
and examined for phospho-Ser253 and total TF. The percentage changes in the phospho-Ser253:total 
TF ratios were calculated against a scrambled-PAR2-AP treated sample. (n=3, *=p<0.05 vs. untreated 
sample, micrographs are representative of 3 experiments). (B) HCAEC (2×105) overexpressing TFWt, 
TFAsp253 or TFAla253, in SFM were activated with PAR2-AP. The cells were lysed and examined for 
phospho-Ser258 and total TF. The percentage changes in the phosphorylated:total TF were calculated 
against a scrambled-PAR2-AP treated sample. (n=4, *=p<0.05 vs. untreated sample, micrographs are 
representative of 4 experiments). 
Fig. 4. Analysis of TF release and phosphorylation in cells transfected with TF-cytoplasmic 
peptides and the influence of Calyculin-A. Cells were placed in SFM and activated with PAR2-AP 
(20 µM) or scrambled-PAR2-AP. (A) Microparticles were isolated at 60 and 90 min and TF 
concentrations determined (n=4, *=p<0.05 vs. scrambled-PAR2-AP-activated samples). (B) HCAEC 
expressing TFWt were transfected with the peptide RKAGVGQpSKENWSPLNVS (pS/S) and adapted 
to SFM. Cells were activated with PAR2-AP (20 µM) and microparticles removed and TF antigen 
concentration measured, up to 150 min (n=3, *=p<0.05 vs. untreated sample). The cells were also 
lysed and examined for phospho-Ser253 and total TF. (micrographs are representative of 3 
experiments). (C) HCAEC (2×105) overexpressing TFWt were transfected with the four forms of the 
TF-peptides or a random-peptide. The ratios of the phospho-Ser258-TF to total TF in the cells was 
determined at 60 and 90 min. (n=4, *=p<0.05 vs. untransfected sample, micrographs are 
representative of 4 experiments collected at 90 min). (D) HCAEC (2×105) overexpressing TFAla258 
were transfected with the peptide RKAGVGQSKENWpSPLNVS (S/pS) and adapted to SFM. 
Calyculin-A (1 nM) was added to one set and incubated for a further 30 min prior to activation of all 
samples with PAR2-AP (20 µM). TF release was determined at 90 min (n=3, *=p<0.05 vs. the control 
sample #=p<0.05 vs. the sample transfected with S/pS peptide but without Calyculin-A). (E) The 
ratios of phospho-Ser253 to total TF were determined at 90 min and percentage phosphorylation 
calculated against an untreated sample. (n=4, *=p<0.05 vs. the control sample, micrographs are 
representative of 4 experiments). (F) HCAEC (2×105) overexpressing TFAsp258 were adapted to SFM 
and Calyculin-A (1 nM) was added to one set and incubated for a further 30 min prior to activation of 
all samples with PAR2-AP (20 µM). TF release was determined at 90 min (n=3, #=p<0.05 vs. the 
sample without Calyculin-A). (G) The ratios of phospho-Ser253 to total TF were determined at 90 
min and percentage phosphorylation calculated against an untreated sample. (micrographs are 
representative of 4 experiments). 
Fig. 5. Putative sequential mechanism of TF incorporation into microparticles. TF = tissue factor; 
PKC = protein kinase C; PS = phosphatidylserine; MP = microparticle; PDK = proline-directed 
kinase; ? = undetermined. 
Fig. 6. Comparison of the protein sequences of the cytoplasmic domain of TF from nine mammalian 
species. 
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Figure 2 
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Figure 5 
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Figure 6 
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